ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy.
 PMID: 22892524       2012       Antiviral therapy
Abstract: METHODS: In 10 HBV-monoinfected patients (9 male, mean age 47 +-11 [range 27-67] years, 6 hepatitis B e antigen-positive) with virological breakthrough during ADV treatment associated with the mutations rtN236T and/or rtA181T/V, HBV polymerase gene variants were studied during up to 24 months of consecutive monotherapy with TDF by population sequencing, line probe assay and clonal analysis.
Abstract: To assess the clinical relevance of this cross-resistance, we studied the evolution of HBV polymerase gene variants in patients with genotypic resistance against ADV (rtN236T and/or rt<


  Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation.
 PMID: 23166535       2012       Hepatitis monthly
Introduction: As for other NAs, the rtN236T mutation is associated with ADV resistance.


  Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
 PMID: 20367795       2011       Journal of viral hepatitis
Abstract: Moreover, rtT184S and rtS202C, which are known entecavir-resistant mutations, emerged in some rtL180M+M204V clones without rtA200V or rtN236T.
Abstract: The rtN236T ADV-resistant mutation was observed in only 25% clones.


  Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.
 PMID: 21392168       2011       Journal of viral hepatitis
Method: The rtA181V and rtN236T were defined as the signature ADV-resistant mutations (ADV-R).
Result: Of the resistance mutations detected in patients who received monotherapies, rtM204I (32.2%), rtM204V + Discussion: Although in vitro phenotyping was not performed in this study, it has been shown that MDR strains with signature mutations to both LAM and ADV (rtM204V + A181V/N236T) have competent replicative capacity in the presence of LAM and ADV and obviously reduced susceptibility to each of the drugs in comparison with wild-type stains [51, 52].


  HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays.
 PMID: 21396961       2011       Journal of virological methods
Abstract: Similarly, patient derived RT genes containing the adefovir resistance (ADV-R) mutations rtA181V or rtN236T demonstrated an ADV-R phenotype.


  [The replication capacity and drug sensitivity of Adefovir dipivoxil-resistant HBV mutants in vivo].
 PMID: 21485198       2011       Sheng wu yi xue gong cheng xue za zhi
Abstract: The anti-ADV mutant HBV plasmid of rtA181V and rtN236T, prepared by Multi Site-Directed Mutagenesis Kit, was transferred into mice via the tail vein, and the levels of HBV-DNA replication were detected after Anti-HBV drugs treatment.


  Detection of lamivudine- or adefovir-resistant hepatitis B virus mutations by a liquid array.
 PMID: 21513743       2011       Journal of virological methods
Abstract: A novel polymerase chain reaction (PCR)-Luminex assay was developed for rapid, accurate, and high-throughput detection of the most important hepatitis B virus (HBV) variants, including those with reverse transcriptase (RT) domain L180M, M204I/V, A181T/V/S, I233V and N236T mutations associated with resistance to lamivudine (LAM) or adefovir (ADV).


  The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
 PMID: 21871497       2011       Antiviral research
Abstract: Furthermore, the effect of a combination of either AT-61 or AT-130 with BAY41-4109, and the combination of these compounds with tenofovir was studied on wild type HBV as well as on a lamivudine and an adefovir-resistant mutant (rtL180M+M204V and rtN236T, respectively).
Abstract: HepG2 stable cell lines permanently expressing wild type (WT) HBV or the main HBV mutants resistant to lamivudine and/or adefovir (rtL180M+rtM204V, rtV173L+rtL180M+rtM204V,


  Evolution of hepatitis B virus during long-term therapy in patients with chronic hepatitis B.
 PMID: 21911882       2011       Annals of hepatology
Abstract: During ADV and LAM treatment, one patient developed ADV plus LAM resistance mutations (rtI163V+rtL180M+rtA181V+rtN236T), in this case, HBV strains harbouring polymerase mutations did not develop LAM associated rtM204V/I primary mutation.
Abstract: RESULTS: Three patients developed LAM resistance mutations (2 presented rtM204I and one rtL180M+rtM204V/I) and one patient showed


  Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naive to antiviral drugs.
 PMID: 21920388       2011       Antiviral research
Abstract: HBV reverse-transcriptase (RT) region was sequenced and analyzed for 20 mutations, confirmed by in vitro studies as associated with resistance to nucleos(t)ide HBV-RT inhibitors (rtL80I/V-rtI169T-rtV173L-rtL180M-rtA181T/V/S-rtT184A/S/G/C-rtA194T-rtS202C/G/I-



Browser Board

 Co-occurred Entities




   Filtrator